Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the present study, we determined whether these goals are reflected in current clinical practice once FH has been diagnosed. METHODOLOGY/PRINCIPAL FINDINGS: In 2008, we sent questionnaires to all subjects (aged 18-65 years) who were molecularly diagnosed with FH in the year 2006 through the screening program in The Netherlands. Of these 1062 subjects, 781 completed the questionnaire (46% males; mean age: 42+/-12 years; mean LDL-C at molecular diagnosis (baseline): 4.1+/-1.3 mmol/L). The number of persons that used cholesterol-lowering therapy increased from 397 (51%) at baseline to 636 (81%) after diagnosis. Mean treated LDL-C levels decreased significantly to 3.2+/-1.1 mmol/L two years after diagnosis. Only 22% achieved the LDL-C target level of < or = 2.5 mmol/L. CONCLUSIONS/SIGNIFICANCE: The proportion of patients using cholesterol-lowering medication was significantly increased after FH diagnosis through genetic cascade screening. The attained LDL-C levels were lower than those reported in previous surveys on medication use in FH, which could reflect the effect of more stringent lipid target levels. However, only a minority of the medication users reached the LDL-C target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some conditions the process of genetic counselling can be optimized and extended with cascade screening, which identifies patients at risk and enables timely treatment of affected relatives, as is the case for familial hypercholesterolaemia.72,75”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241 · cited 1×
“20 based on the approximately 17% additional LDL-C lowering when added to statins.[14] The potency of a resin was estimated as 1.”
BackgroundSelf-citationSmilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationEfficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
Self-citationRISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATES
Slack, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90930-1 · Cited by 623
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
Umans-Eckenhausen, M. A., Defesche, J. C., Sijbrands, E. J., Scheerder, R. L., & Kastelein, J. J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03587-x · Cited by 489
Self-citationPleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 407
Pijlman, A. H., Huijgen, R., Verhagen, S. N., Imholz, B. P. M., Liem, A. H., Kastelein, J. J. P., Abbink, E. J., Stalenhoef, A. F. H., & Visseren, F. L. J. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.014 · Cited by 238
Self-citationFamilial hypercholesterolaemia: summary of NICE guidance
Wierzbicki, A. S., Humphries, S. E., Minhas, R., & on behalf of the Guideline Development Group (2008) · BMJ · doi:10.1136/bmj.a1095 · Cited by 237
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Josan, K., Majumdar, S. R., & McAlister, F. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070675 · Cited by 201
Neil, H. A. W. (2000) · BMJ · doi:10.1136/bmj.321.7254.148 · Cited by 186
Rose, S. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92069-5 · Cited by 183
Update of the molecular basis of familial hypercholesterolemia in The Netherlands
Fouchier, S. W., Kastelein, J. J. P., & Defesche, J. C. (2005) · Human Mutation · doi:10.1002/humu.20256 · Cited by 154
Self-citationUmans-Eckenhausen, M. A. W., Sijbrands, E. J. G., Kastelein, J. J. P., & Defesche, J. C. (2002) · Circulation · doi:10.1161/01.cir.0000041253.61683.08 · Cited by 100
Self-citationAbifadel, M., Rabès, J.-P., Jambart, S., Halaby, G., Gannagé-Yared, M.-H., Sarkis, A., Beaino, G., Varret, M., Salem, N., Corbani, S., et al. (2009) · Human Mutation · doi:10.1002/humu.21002 · Cited by 99
Leren, T. P., Finborud, T. H., Manshaus, T., Ose, L., & Berge, K. E. (2008) · Public Health Genomics · doi:10.1159/000111637 · Cited by 87
Umans-Eckenhausen, M. A. W., Defesche, J. C., van Dam, M., & Kastelein, J. J. P. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.1.65 · Cited by 87
Self-citationNeil, H. A. W., Seagroatt, V, Betteridge, D. J., Cooper, M. P., Durrington, P. N., Miller, J. P., Seed, M., Naoumova, R. P., Thompson, G. R., Huxley, R., et al. (2004) · Heart · doi:10.1136/hrt.2003.022764 · Cited by 85
Familial hypercholesterolemia: current treatment and advances in management
Huijgen, R., Vissers, M. N., Defesche, J. C., Lansberg, P. J., Kastelein, J. J., & Hutten, B. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.4.567 · Cited by 71
Self-citationGotto, A. M., Bierman, E. L., CONNOR, W. E., Ford, C. H., Frantz, I. D., Glueck, C. J., Grundy, S. M., & Little, J. A. (1984) · PubMed · Cited by 62
Huijgen, R., Sjouke, B., Vis, K., de Randamie, J. S. E., Defesche, J. C., Kastelein, J. J. P., Hovingh, G. K., & Fouchier, S. W. (2012) · Human Mutation · doi:10.1002/humu.21660 · Cited by 46
Self-citationWalma, E., Visseren, F. L. J., Jukema, J. W., Kastelein, J. J. P., Hoes, A. W., & Stalenhoef, A. F. H. (2006) · PubMed · Cited by 37
Self-citationHadfield, S. G., Horara, S., Starr, B. J., Yazdgerdi, S., Bhatnagar, D., Cramb, R., Egan, S., Everdell, R., Ferns, G. A., Jones, A. F., et al. (2008) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2007.007078 · Cited by 33
Souverein, O. W., Defesche, J. C., Zwinderman, A. H., Kastelein, J. J. P., & Tanck, M. W. T. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl366 · Cited by 33
Self-citationFamilial Defective Apolipoprotein B Versus Familial Hypercholesterolemia: An Assessment of Risk
Fouchier, S. W., Defesche, J. C., Kastelein, J. J. P., & Sijbrands, E. J. G. (2004) · Seminars in Vascular Medicine · doi:10.1055/s-2004-861493 · Cited by 31
Self-citationvan der Graaf, A., Fouchier, S. W., Vissers, M. N., Defesche, J. C., Wiegman, A., Sankatsing, R. R., Hutten, B. A., Trip, M. D., & Kastelein, J. J. P. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00022 · Cited by 15
Self-citationHuijgen, R., Kindt, I., Fouchier, S. W., Defesche, J. C., Hutten, B. A., Kastelein, J. J. P., & Vissers, M. N. (2009) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(09)71195-x · Cited by 2
Self-citationFouchier, S. W., Huijgen, R., Vis, K., Defesche, J. C., & Kastelein, J. J. P. (2009) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(09)70991-2 · Cited by 2
Self-citation
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
Metadata
- Authors
- Huijgen, R., Kindt, I., Verhoeven, S. B. J., Sijbrands, E. J. G., Vissers, M. N., Kastelein, J. J. P., & Hutten, B. A.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Erasmus MC (NL)
- Corresponding author
- Huijgen, Roeland
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-02-15
- Volume
- 5
- Issue
- 2
- Pages
- e9220
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2821409
- OpenAlex
- W2124402284
- Cited by
- 124
- References
- 30
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 11 · 2019: 6 · 2018: 11 · 2017: 8 · 2016: 14 · 2015: 11 · 2014: 9 · 2013: 14 · 2012: 16
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
- UvA-DARE (University of Amsterdam) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Pure Amsterdam UMC (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Rijksinstituut voor Volksgezondheid en Milieu
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- familial hypercholesterolemia, cholesterol-lowering therapy, LDL cholesterol targets, cardiovascular risk reduction, treatment goals
- MeSH terms
- Adolescent, Adult, Aged, Anticholesteremic Agents, Apolipoproteins B, Follow-Up Studies, Genetic Testing, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Middle Aged, Mutation, Netherlands, Surveys and Questionnaires, Receptors, LDL, Time Factors, Outcome Assessment, Health Care, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.